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Type 2 diabetes mellitus and cancer are correlated with changes in insulin signaling, a pathway that is frequently
upregulated in neoplastic tissue but impaired in tissues that are classically targeted by insulin in type 2 diabetes
mellitus. Many antidiabetes treatments, particularly metformin, enhance insulin signaling, but this pathway can be
inhibited by specific cancer treatments. The modulation of cancer growth by metformin and of insulin sensitivity by
anticancer drugs is so common that this phenomenon is being studied in hundreds of clinical trials on cancer.
Manymeta-analyses have consistently shown amoderate but direct effect of body mass index on the incidence of
multiple myeloma and lymphoma and the elevated risk of leukemia in adults. Moreover, new epidemiological and
preclinical studies indicate metformin as a therapeutic agent in patients with leukemia, lymphomas, and multiple
myeloma. In this article, we review current findings on the anticancer activities of metformin and the underlying
mechanisms from preclinical and ongoing studies in hematologic malignancies.
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’ INTRODUCTION
Based on the increasing incidence of cancer along with
increasing rates of obesity and type 2 diabetes mellitus (DM2),
much effort has been made to identify the epidemiological
and biological connections between these conditions. In the
clinic, oncologists are gradually being required to tailor cancer
treatments for patients with pre-existing diabetes or obesity,
and endocrinologists often need to control diabetes in patients
who are undergoing treatments for cancer (1).
Despite contradictory reports in the early literature (2-4),
many meta-analyses have consistently shown a moderate
but direct effect of body mass index (BMI) on the incidence of
lymphoma and multiple myeloma (MM) and the elevated
risk of leukemia in adults (5-8). Similarly, patients with DM2
frequently develop hematological malignancies (9-11). Notably,
the incidence of tumors in patients with DM2 is profoundly
affected by the treatment—long-term metformin use has been
found to be connected with a reduced incidence of cancer
and cancer-related mortality (2).
In this review, the association between hematological
cancers and diabetes and the epidemiological, clinical, and
preclinical data that establish the value of metformin as
a potential treatment for hematologic malignancies are
summarized.
Diabetes and cancer
Although the link between DM2 and carcinogenesis was
first reported in 1910 by Maynard and Pearson (1910 apud
Wojciechowska, 2016) (10), it was over 100 years later that
the American Diabetes Association (ADA) and American Society
of Clinical Oncology (ASCO) presented their consensus on the
factors that link diabetes and cancer (10,12). Notably, DM2
and cancer share many risk factors, especially obesity (12),
and DM2 and malignancies are correlated through several
conditions, such as hyperinsulinemia (due to resistance to
endogenous or exogenous insulin), hyperglycemia, and chronic
inflammation due to overweight and body fat mass (10,12).
Adiposity has been correlated with an increased risk of
several cancers, including breast, endometrial, pancreatic,
and colon cancer. In addition, obese men and women with
esophageal, gallbladder, colorectal, pancreatic, liver, and
kidney cancer have an elevated risk of cancer-related deaths
(Table 1) (13). Notably, BMI consistently has a moderate but
direct effect on the rates and risk of death due to lymphoma
and MM and is associate with an increased risk of leukemia
in adults (Table 2) and of monoclonal gammopathy of uncertain
significance (MGUS) transforming into MM (3,6-8,3-26).
Mechanistically, obesity—a state of excess nutrient levels—
chronically activates signaling pathways that upregulate
insulin, insulin-like growth factor (IGF), leptin, and inflam-
matory cytokines (e.g., IL-6) and increases the risk of neo-
plastic transformation. Consistent with this model, elevated
levels of adiponectin, a marker of reduction in adipose tissue,
were recently found to be associated with a lower risk of
MM (27,28). These factors stimulate cell surface receptors
and signaling through Janus kinase (JAK)/signal transducers
and activators of transcription (STATs), mitogen-activated
protein kinase (MAPK), and phosphatidylinositol 3-kinase
(PI3K), and all of these molecules are commonly dysregulated
in neoplastic cells (29).
Conversely, studies worldwide have shown that DM2 is asso-
ciated with increased rates of many cancers and cancer-relatedDOI: 10.6061/clinics/2018/e412s
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mortality (Table 3) (36-47). Notably, DM2 is linked with the
incidence of solid tumors and an increased risk of lymphoma,
leukemia, and MM. A meta-analysis of 26 studies observed
an increased risk of non-Hodgkin lymphoma (NHL) and
peripheral T cell lymphoma (PTCL), unlike other subtypes of
NHL, among patients with DM2. DM2 patients have a risk of
1.22 of developing leukemia (95% confidence interval (CI),
1.03-1.44; P=0.02) and a nonsignificant high risk for devel-
oping myeloma (1.22, 95% CI, 0.98-1.53; P=0.08) (48). Further,
peak postload glucose levels were correlated with an
increased risk of mortality from MM, NHL, and leukemia
in the study by Chiu et al. (49). A recent review concluded
that the association between DM2 and various cancers is
supported by strong evidence in only 14% (breast cancer,
intrahepatic cholangiocarcinoma, colorectal cancer (CRC),
and endometrial cancer) of the 27 correlations investigated,
with no bias (50).
As the incidence of DM2 is increasing worldwide, MM,
leukemia, and NHL are being diagnosed more frequently
with concomitant diabetes mellitus (9,48,51-53). Therefore,
physicians who treat patients with these comorbidities must
consider the possible effects of the treatments for MM and
leukemia on glucose metabolism (54,55).
Antihyperglycemic agents and the risk of cancer. Early
studies have observed that compared to no therapy, met-
formin monotherapy is correlated with a reduced risk of
developing cancer, whereas sulfonylurea therapy is correlated
with an increased risk (59). These observations led to the
hypothesis that hypoglycemic agents differentially influence
the risk of cancer, depending on the concentrations of insulin
that they induce (60).
Although an initial meta-analysis failed to detect an
elevated cancer risk in association with the use of insulin, the
meta-analysis had small sample sizes and short durations
of study (61,62). Consistent with the above hypothesis, a sub-
sequent meta-analysis in larger populations demonstrated an
increase in the overall cancer risk (relative risk [RR] 1.39; 95%
CI: 1.14-1.70) correlated with insulin therapy (63-65).
In contrast, a recent meta-analysis reported mixed results
concerning insulin secretagogues and the risk of cancer,
demonstrating a correlation between the administration of
sulfonylureas and an increased risk of some cancers but not
others (66,67). In addition, a recent randomized controlled
study of over 12,000 patients (average follow-up over six years)
Table 2 - Incidence of hematological malignancies in obese patients.
Hematologic
malignancy
Patient cohort and study
Lymphoma Meta-analysis: RRs for a 5 kg/m(2) increase in BMI were 1.07 (95% confidence interval [CI], 1.04-1.10) for NHL incidence
(16 studies, n=17,291 cases) and 1.14 (95% CI, 1.04-1.26) for NHL mortality (five studies, n=3407 cases) (7).
MM Meta-analysis: RRs were 1.12 (95% CI, 1.07-1.18) for overweight individuals and 1.21 (95% CI, 1.08-1.35) for obese individuals;
a total of 15 cohort studies on MM incidence and five studies on MM mortality were included (8).
Leukemia Meta-analysis: RRs of leukemia were 1.14 [95% CI, 1.03-1.25] for overweight individuals (BMI 25-30 kg/m(2)) and 1.39 (95% CI,
1.25-1.54) for obese individuals (BMI4or= 30 kg/m(2)); a total of 9 cohort studies with data on BMI or obesity in relation to the
incidence of leukemia were included (6).
Subtypes of
leukemia
Meta-analysis: RRs associatedwith obesity were 1.25 (95% CI, 1.11-1.41) for CLL, 1.65 (95% CI, 1.16-2.35) for ALL, 1.52 (95% CI, 1.19-1.95)
for AML and 1.26 (95% CI, 1.09-1.46) for CML; a total of 4 studies reporting results on subtypes of leukemia were included (6).
ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, BMI: body mass index, CLL: chronic lymphocytic leukemia, CML: chronic myeloid
leukemia, MM: multiple myeloma NHL: Non-Hodgkin Lymphoma, RR: relative risk.
Table 1 - Relative risks associated with overweight and obesity and percentage of cases attributable to overweight and obesity in the
United States, the European Union, and Brazil.
Type of cancer RR* BMI
25-30 kg/m2
RR* BMI
430 kg/m2
FAP* (%) for
the US (30, 31)
FAP (%) for
the EU (22, 32-34)
FAP (%) for
BR (35)
Colon cancer (men) 1.5 2.0 35.4 27.5 43.8
Colon cancer (women) 1.2 1.5 20.8 14.2 25.3
Breast cancer (postmenopausal women) 1.3 1.5 22.6 16.7 17.3
Endometrial cancer 2.0 3.5 56.8 45.2 44.8
Kidney (kidney cells) cancer 1.5 2.5 42.5 31.1 31.3(W)/35.6(M)
Adenocarcinoma of the esophagus 2.0 3.0 53.4 42.7 60.2(W)/72.8(M)
Pancreatic cancer 1.3 1.7 26.9 19.3 24.7(W)/33.9(M)
Hepatocellular carcinoma ND* 1.5-4 ND* ND* 23.9(W)/25.9(M)
Gall bladder 1.5 2.0 35.5 27.1 18.2(W)/6.6(M)
Cardiac adenocarcinoma 1.5 2.0 35.5 27.1 62.2(W)/65.5(M)
*RR: relative risk, FAP: fraction attributable to population, BMI: body mass index, ND: not determined, W: women, M: men. USA: United States of America,
EU: Europe; BR: Brazil.
Table 3 - Meta-analysis on the relative risk (RR) of cancer in
different organs in patients with diabetes.
Type of cancer
(author and year)
Number of
evaluated studies
RR
(95% CI*)
Colon (Luo et al. 2012) (36) 24 1.27 (1.14-1.42)
Breast (Boyle et al. 2012) (37) 40 1.27 (1.16-1.39)
Pancreatic (Ben et al. 2011) (38) 35 1.94 (1.66-2.27)
Prostate (Long et al. 2012) (42) 7 2.82 (1.73-4.58)
Prostate (Hwang et al. 2015) (56) 8 1.20 (1.00-1.44)
Liver (Chen et al. 2015) (43) 21 1.86 (1.49-2.31)
Lung (Zhu et al. 2016) (57) 20 1.28 (1.10-1.49)
Bladder (Fang et al. 2013) (44) 24 1.30 (1.18-1.43)
Ovarian (Lee et al. 2013) (58) 18 1.16 (1.01-1.33)
*CI: confidence interval, RR: relative risk.
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failed to demonstrate an increase in the rates of cancer or
cancer-specific mortality in insulin users versus controls (68).
However, a large meta-analysis of 182 randomized controlled
trials including 135,540 patients with diabetes linked the use
of metformin and thiazolidinediones (TZDs) with a reduced
risk of cancer (69). These reviews suggest that the insulin level
is not a surrogate marker of cancer development, thereby
indicating a unique mechanism of metformin activity in
cancer.
Metformin, cancer, and onco-hematological
diseases
History of metformin. Metformin is a derivative of
biguanide that has been used for nearly one century to treat
DM2. Biguanides initially derived from Galega officinalis
(Leguminosae) (or goat's rue), French lilac, Spanish sainfoin,
and false indigo have been recognized for their medicinal value
since medieval times in Europe (Figure 1) (70). G. officina-
lis—arruda-caprária in Brazil—is a medicinal plant that
originated in Europe and Asia (62-64), and its medicinal
properties have been recognized since medieval times, during
which G. officinalis was prescribed in folk medicine to relieve
polyuria accompanying DM2 (71).
Although G. officinalis reduces glucose concentration in
blood of patients with diabetes, the search for its active
compound has been slow, primarily due to the effects of
light on this plant and the introduction of insulin. Studies
at the end of the 19th century indicated that G. officinalis
was rich in guanidine, and in 1918, guanidine was shown to
have hypoglycemic activity in animals. Nonetheless, guani-
dine was incredibly toxic for clinical use, prompting interest
in galegine (isoamylene guanidine) (71).
In 1929, several biguanides that reduced serum glucose
levels, including dimethyl biguanide (1,1-dimethyl biguanide
hydrochloride or metformin), were synthesized. Jean Sterne
(1909-1997) was the first to perform studies with galegine.
Sterne selected dimethyl biguanide (metformin) for clinical
development and proposed the name Glucophage. In con-
trast to sulfonylureas, metformin fails to induce insulin
secretion but impedes the release of glucose by the liver and
increases muscle glucose uptake (71).
Interestingly, the benefits of metformin in the treatment
of diabetes have gained prominence only since 1995. The
United Kingdom Prospective Diabetes Study (UKPDS) was a
milestone project showing that regardless of glycemic con-
trol, metformin reduced the risk of myocardial infarction and
all-cause mortality. Consequently, diabetes experts around
the world indicated metformin as the first-choice drug for
DM2 (70), and metformin has become the most frequently
administered agent to treat DM2 (72,73).
In 1995, the benefits of metformin in people with diabetes
were found to not only be limited to glycemic control, and
metformin was shown to reduce the risk of malignancy in
patients with diabetes. Evans et al. (2) were the first group to
note an inverse correlation between cancer and metformin
use, wherein patients who were exposed to metformin had a
low risk of developing cancer. Since then, various studies in
DM2 patients have shown that metformin use is associated
with a reduced risk of several cancers (2,11,74-79), includ-
ing prostate cancer (80,81), lung cancer (45,82,83), head and
neck cancer (HNC) (84,85), breast cancer (86-88), pancreatic
cancer (89), CRC (90-92), endometrial cancer (93), ovarian cancer
(94-96) and hepatocellular carcinoma (HCC) (97,98) (Table 4).
Mechanisms of action of metformin and preclinical
and ongoing studies in hematologic malignancies. Two
potential accepted antineoplastic mechanisms of metformin
have been proposed (Figure 2). First, metformin inhibits mito-
chondrial complex 1, resulting in low ATP production and an
increase in the concentration of ADP; ADP is transformed to
AMP by the catalytic effect of the enzyme adenylate kinase.
Under low ATP concentrations, AMP binds to the g subunit
of AMPK leading to some conformational changes in the
a subunit, and this favors the phosphorylation of AMPK (72).
Moreover, the inhibition of complex 1 produces reactive
nitrogen species. These radicals stimulate protein kinase
C z (PKCz), which successively phosphorylates LKB1L and
LKB1S, thereby leading to the activation of LKB1. Activated
LKB1 phosphorylates and activates AMPK (90), resulting in
the inhibition of downstream AKT/mTOR signaling and
consequent suppression of cell proliferation (100,101). Second,
metformin induces reductions in circulating insulin con-
centrations and IGF, preventing the activation of the insu-
lin and IGF receptor signaling pathways and resulting in
decreased growth promotion and mutagenesis (102,103).
Notably, IGF-1 and insulin receptors interact to implement
antiapoptotic signaling that increases AKT/mTOR kinase
activity (104,105).
Despite the importance of LKB1 in the AMPK-depen-
dent antineoplastic effects of metformin, this drug abolishes
the increase in tumor growth linked with high-fat diet and
hyperinsulinemia, irrespective of LKB1 expression by the
tumor. This antineoplastic activity is connected with decreased
circulating insulin levels and insulin receptor activation in
tumoral tissues, similar to the mechanisms underlying
tumor growth repression by dietary control (106-109).
Many studies have shown that metformin synergizes
with chemotherapeutic drugs at low doses, minimizing the
Figure 1 - Galega officinalis (goat’s rue). http://www.findme
plants.co.uk/photos/galega_officinalis.jpg
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side effects of high doses (99,110,111). More than 40 phase
I/II clinical cancer trials (http://clinicaltrials.gov/) on
metformin in combination with chemotherapeutics are under-
way worldwide. These studies are examining the antineo-
plastic effects of metformin. This drug is used jointly with
chemotherapeutic agents in cancers of the digestive (hepatic,
gastric, pancreatic, and colorectal) and reproductive systems
(ovarian and endometrial) and lung, prostate, and breast
cancer, and the clinical limitations of metformin in cancer treat-
ment are being determined. Several trials have reported
synergistic or additive effects of such combinations (87,111-131).
In contrast, observational retrospective studies have observed
that these combinations are antagonistic in certain cancers
(132-136). Therefore, metformin synergizes with standard
chemotherapy drugs to increase chemosensitivity in specific
cancers.
Cell metabolism is epigenetically regulated (137,138).
Cells control their metabolism in response to extracellular
signals and the availability of nutrients by altering their epi-
genetic and transcriptional programs. Notably, metformin
is also involved in this cooperation between epigenetic and
metabolic mechanisms. Du et al. (139) found that metformin
decreases histone H2B (H2BK120) and monoubiquitination
levels and inhibits the transcription of target genes, such as
cyclin D1 and p21. Metformin-activated AMPK increases
the histone deacetylase activity of SIRT1 to downregulate
acetylated p53 and p21 levels (140). Further, the loss of the
MM SET domain (MMSET) in MM cells (141) is regulated by
metformin in prostate cancer cells (142). Finally, metformin
decreases the levels of a histone demethylase coactivator (143)
and a metabolic enzyme in the TCA cycle (144,145).
Myeloma and metformin. AKT mediates the pathogen-
esis and progression of MM and resistance to standard treat-
ments. Many upstream signaling pathways converge on AKT
to govern survival and proliferative signals and apoptosis
suppression. Early data have revealed high expression of
AKT in myeloma cell lines and bone marrow aspirates from
patients, especially in the advanced stages (105). In accor-
dance, in vitro and in vivo, the combination of metformin and
dexamethasone synergizes to eliminate MM cells, inhibiting
cell proliferation through reduced AKT/mTOR signaling (146).
This phenomenon is mediated by the phosphorylation of
TSC2 (147), which negatively regulates cell growth by acting
upstream of mTOR (148).
Notably, metformin inhibits glucose regulatory protein 78
(GRP78), an essential factor in bortezomib-induced auto-
phagy and pharmacologically increases the anti-myeloma effects
of bortezomib. Concomitant treatment with metformin and bor-
tezomib inhibits the effects of the unfolded protein response
(UPR) on GRO78, thus impairing autophagosome formation and
increasing apoptosis and confirming the impeded growth of
xenotransplanted myeloma cells in vivo (149).
The low toxicity and potent in vitro and in vivo effects
of metformin, in combination with the findings of retrospective
epidemiological studies in various cancer models, have prompted
nearly 200 trials (ClinicalTrials.gov) examining metformin
Figure 2 - The insulin-dependent (indirect effects) and AMPK-dependent molecular mechanisms (direct effects) underlying the
anticancer effects of metformin. AMPK activation in the liver results in decreased insulin and IGF-1 levels and consequent attenuated
downstream signaling. In cancer cells, AMPK inhibits PI3K/AKT/mTORC1 signaling directly through the phosphorylation of the Raptor
subunit and indirectly through the phosphorylation of the TSC1/2 complex and insulin receptor substrate 1 (IRS1) and the activation of
regulated in development and DNA damage response 1 (REDD1). In addition, metformin-induced activation of AMPK leads to the
phosphorylation of p53, inducing cycle arrest, apoptosis and autophagy. Inhibition of mTORC1 results in a decrease in global protein
synthesis and lipogenesis. Metabolic alterations are also achieved by the inhibition of acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) reductase.
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alone or in combination with other antitumoral agents in
patients without diabetes. However, few studies are determin-
ing the effects of metformin in MM (Table 5).
Leukemias and metformin. The LKB1/AMPK/mTOR
axis functions in hematopoietic cancers, such as acute myeloid
leukemia (AML) and acute lymphoblastic leukemia (ALL);
consequently, metformin represents a new perspective in
hematological cancer therapy. Nevertheless, metformin does
not appear to alter the growth, differentiation, or survival of
normal CD34+ stem cells (150-152).
Mutations/deletions in PTEN or post-translational inhibi-
tion of its lipid phosphatase activity is responsible for much
of the chronic stimulation of PI3K/AKT/mTOR signaling in
T-ALL (153). In accordance, deletion of LKB1 in mice on a
PTEN+/- background increases the incidence of various
tumors, including lymphomas, the development of which
is significantly delayed by metformin (154). Thus, metformin
might increase the chemosensitivity of ALL through its
inhibitory effects on the AKT/mTOR pathway via AMPK
activation (155,156).
Insulin might contribute to the chemoresistance of ALL
cells by activating PI3K/AKT/mTOR signaling. IGF-1 signal-
ing increases the proliferation of cell lines (157,158) and
inhibits dexamethasone-induced apoptosis (158), promoting
the growth of malignant cells. Thus, elevated levels of exoge-
nous insulin might activate insulin and IGF-1 receptor (IGF-1R)
on ALL blasts (157), a phenomenon that can be blocked
through a metformin-mediated reduction in insulin levels.
The PI3K/AKT/mTOR pathway is also stimulated by
upstream oncogenes, such as the protein kinase BCR-ABL,
a t(9,22) translocation product in chronic and acute Ph1+
leukemias, and the Tax oncoprotein, which is central in
the pathogenesis of HTLV human retrovirus infection and
adult T cell leukemia. Through the activation of AMPK, met-
formin suppresses the proliferation and clonogenic activity
of several chronic myeloid leukemia (CML) lines, such as those
that are imatinib-resistant and T315I BCR-ABL mutants (152).
In leukemic stem cells and stem cells of solid tumors,
metformin is selective toward inducing death in vitro and
tumor xenografts (159). These findings are notable because the
leukemic stem cells that persist despite antineoplastic treat-
ment are one of the causes of neoplasia relapse (160).
When combined with chemotherapy or other drugs, met-
formin might have additive effects on reducing cell growth
and drug efflux through its activity on AMPK or P-glycoprotein
(161,162). In acute promyelocytic leukemia (APL), metformin
synergizes with trans-retinoic acid, inducing the differentiation
and apoptosis in leukemic blasts (163). An examination of glucose
dependence in chronic lymphocytic leukemia (CLL) cells dem-
onstrated differential sensitivity to glucose deprivation; thus, the
administration of the HIV protease inhibitor ritonavir and metfor-
min to CLL cells has provided a strong rationale to target glucose
metabolism and the ensuing metabolic plasticity in CLL (164).
Based on these findings, future studies should examine
the role of metformin in improving chemotherapy outcomes
in ALL patients with or without diabetes. Many trials are
testing metformin in patients without diabetes who have
solid tumors. Four recent clinical trials (ClinicalTrials.gov)
are measuring the clinical and biological outcomes of met-
formin combined with standard systemic chemotherapy in
relapsed ALL (Table 6), and their findings will be reported soon.
Lymphoma and metformin. Shi et al. (165) have pro-
vided the first evidence of the in vitro and in vivo activity of
metformin in human lymphoma cells, demonstrating that
the activity of drug on AMPK inhibits the growth of B and
T cell lymphomas by inhibiting mTOR signaling without the
involvement of AKT. Moreover, the response of lymphoma
to drugs such as doxorubicin and temsirolimus, a mTOR
inhibitor, is significantly improves upon coadministration with
metformin. In addition to inhibiting the mTOR pathway,
metformin activates p53 by suppressing murine double
minute X (MDMX), thereby causing apoptosis (166).
Rosilio et al. (167) demonstrated that metformin, phenfor-
min, and AICAR, an AMPK activator, have robust antitumor
Table 5 - Ongoing clinical studies with metformin in MM.
Type of disease Disease status Type of study Associated drugs Country of study ClinicalTrials.gov identifier
MM* or CLL* Recurrent/refractory Pilot Ritonavir USA* NCT02948283
MM* Recurrent/refractory Phase II High doses of dexamethasone BR* NCT02967276
*MM: multiple myeloma, CLL: chronic lymphocytic leukemia, USA: United States of America, BR: Brazil.
Table 6 - Ongoing clinical studies with metformin in leukemias and lymphomas.
Type of disease Disease status Type of
study
Associated drugs Country of
study
ClinicalTrials.gov
identifier
CLL* Relapsed and untreated disease Pilot None USA* NCT01750567
CLL* or MM* Recurrent/refractory Pilot Ritonavir USA* NCT02948283
ALL Relapsed Phase I Vincristine, dexamethasone,
doxorubicin, and
PEG-asparaginase
USA* NCT01324180
AML* Relapsed and refractory Phase I Cytarabine USA* NCT01849276
NHL* other solid tumors Relapsed and refractory to other treatments Phase I Sirolimus USA* NCT02145559
NHL* other solid tumors Relapsed and refractory to other treatments Phase I Temsirolimus Canada NCT00659568
DLBCL* Previously, untreated Phase II R-CHOP USA* NCT02531308
DLBCL* Double-hit lymphoma Phase II DA-EPOCH-R USA* NCT02815397
*ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, CLL: chronic lymphocytic leukemia, DA-EPOCHR: dose-adjusted etoposide+ prednisone
+ vincristine + cyclophosphamide + doxorubicin + rituximab, MM: multiple myeloma, NHL: non-Hodgkin lymphoma, DLBCL: diffuse large B cell
lymphoma, R-CHOP: rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone, USA: United States of America.
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activities against human T-LEN and human T-ALL lines. The
mechanism of action of these agents is to suppress tumor meta-
bolism and proliferation by inducing apoptosis, activating
AMPK, and constitutively inhibiting mTOR. Further, several
signal transduction pathways [mTOR, AKT, NF-kappaB
(NF-kB), Fatty acid synthase (FASN), and insulin-like growth
factor-1 receptor (IGF-1R)] are overexpressed in Peripheral
T-cell lymphomas (PTCL), supporting the use of metformin
as an inhibitor of mTORC2 and NF-kB in PTCL (168).
In diffuse large B cell lymphoma (DLBCL) patients with
diabetes, metformin, as a first-line chemoimmunotherapeutic
agent with rituximab, improved progression-free survival
(PFS; 94 months vs. 55.4 months, P=0.007) and overall sur-
vival (OS; 100 months vs. 70.5 months, P=0.031) compared
with other antidiabetogenic agents (169). Despite the impres-
sive results of this retrospective trial, only four ongoing
clinical trials (ClinicalTrials.gov) are evaluating the effects of
metformin with standard systemic chemotherapy in the
settings of relapsed and refractory NHL (Table 6).
The combined increase in the occurrence of diabetes,
obesity, and cancer has created a significant problem in
which complex disease pathophysiologies are intertwined.
Dissection of the epidemiological and molecular links
between these diseases has revealed novel target molecules
and new treatment opportunities. In conjunction with inter-
disciplinary research, epidemiological and preclinical data
support that metformin benefits select patients with solid
tumors and hematological tumors; however, strict clinical
trials are required to pinpoint patients who might benefit
from metformin combinations. Thus, we need to assess
whether the anticancer effects of metformin depend on meta-
bolic variables, such as diabetes, BMI, insulin resistance, and
obesity-related inflammation.
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